Merck, Inc.
A Study to Evaluate Molnupiravir Tablet Formulation Compared to the Molnupiravir Capsule Formulation in Healthy Adult Participants (MK-4482-011)
- Conditions
- Healthy
- Interventions
- Drug: Molnupiravir
- First Posted Date
- 2024-09-27
- Last Posted Date
- 2024-09-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 64
- Registration Number
- NCT06615869
- Locations
- 🇺🇸
QPS-MRA, LLC-Early Phase (Site 0002), South Miami, Florida, United States
A Clincal Study of Enlicitide and the Effect of Food in Healthy Adult Participants (MK-0616-033)
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 20
- Registration Number
- NCT06609512
- Locations
- 🇺🇸
Celerion ( Site 0001), Tempe, Arizona, United States
A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 65
- Registration Number
- NCT06611033
- Locations
- 🇺🇸
Velocity Clinical Research, Hallandale Beach ( Site 0003), Hallandale Beach, Florida, United States
🇺🇸Research Centers of America ( Hollywood ) ( Site 0002), Hollywood, Florida, United States
🇺🇸University of Texas Medical Branch ( Site 0001), Galveston, Texas, United States
A Study to Compare Oral Formulations of Tedizolid Phosphate in Healthy Adults (MK-1986-044)
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2024-09-24
- Last Posted Date
- 2024-09-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT06609161
- Locations
- 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States
A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT06597760
- Locations
- 🇺🇸
Celerion ( Site 0001), Lincoln, Nebraska, United States
Drug-Drug Interaction Study of Bomedemstat and Carbamazepine in Healthy Adult Participants (MK-3543-020)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 16
- Registration Number
- NCT06596668
- Locations
- 🇺🇸
Celerion, Inc. ( Site 0001), Tempe, Arizona, United States
A Study to Evaluate the Effects of Itraconazole on MK-1708 in Healthy Participants (MK-1708-003)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT06586606
- Locations
- 🇺🇸
QPS-MRA, LLC ( Site 0001), South Miami, Florida, United States
Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 130
- Registration Number
- NCT06596694
- Locations
- 🇺🇸
University of Chicago Medical Center ( Site 1204), Chicago, Illinois, United States
🇺🇸UCLA Hematology Oncology Santa Monica ( Site 1205), Santa Monica, California, United States
🇺🇸Sibley Memorial Hospital ( Site 1208), Washington, District of Columbia, United States
A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)
- First Posted Date
- 2024-09-12
- Last Posted Date
- 2024-09-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 24
- Registration Number
- NCT06592339
- Locations
- 🇺🇸
QPS-MRA, LLC-Early Phase, South Miami, Florida, United States
A Study to Compare Forms of Nemtabrutinib (MK-1026) in Healthy Adult Participants (MK-1026-007)
- First Posted Date
- 2024-09-06
- Last Posted Date
- 2024-09-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 40
- Registration Number
- NCT06586671
- Locations
- 🇺🇸
QPS-MRA, LLC-Early Phase (Site 0002), South Miami, Florida, United States